Table 2.
Mean scores and prevalences for the total sample and by diagnosis
| Diagnosis | Physical function | Role function | Emotional function | Social function | Cognitive function | Quality of life | Pain | Fatigue | Nausea/ emesis | Dyspnoea | Appetite loss | Insomnia | Diarrhoea | Constipation | Financial difficulties | Mean no. of ‘symptoms’ | Mean no. of ‘severe symptoms’ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total N = 470 | Mean score | 77 | 69 | 82 | 82 | 81 | 67 | 23 | 35 | 5 | 18 | 13 | 22 | 10 | 9 | 10 | 4.3 | 1.5 |
| % symptoms | 34% | 49% | 24% | 30% | 31% | 37% | 55% | 8% | 36% | 25% | 46% | 21% | 20% | 19% | ||||
| % severe symptoms | 9% | 23% | 5% | 10% | 9% | 15% | 20% | 2% | 15% | 11% | 15% | 6% | 6% | 7% | ||||
| AML N = 34 | Mean score | 86 | 75 | 79 | 85 | 79 | 74 | 10 | 34 | 5 | 12 | 12 | 19 | 7 | 2 | 10 | 3.7 | 0.9 |
| % symptoms | 18% | 38% | 30% | 30% | 33% | 24% | 47% | 6% | 24% | 24% | 56% | 15% | 6% | 21% | ||||
| % severe symptoms | 3% | 18% | 3% | 3% | 12% | 3% | 18% | 0% | 6% | 12% | 0% | 6% | 0% | 6% | ||||
| CLL N = 132 | Mean score | 76 | 71 | 84 | 85 | 82 | 67 | 22 | 35 | 5 | 21 | 12 | 25 | 11 | 11 | 6 | 4.0 | 1.4 |
| % symptoms | 36% | 46% | 21% | 21% | 27% | 37% | 55% | 8% | 40% | 26% | 48% | 22% | 23% | 14% | ||||
| % severe symptoms | 8% | 22% | 4% | 10% | 8% | 14% | 22% | 2% | 19% | 8% | 18% | 8% | 7% | 4% | ||||
| CML N = 34 | Mean score | 81 | 71 | 85 | 83 | 82 | 71 | 25 | 33 | 10 | 22 | 14 | 20 | 11 | 5 | 8 | 4.2 | 1.5 |
| % symptoms | 26% | 45% | 25% | 31% | 25% | 32% | 53% | 21% | 44% | 29% | 35% | 31% | 13% | 16% | ||||
| % severe symptoms | 6% | 21% | 6% | 3% | 9% | 24% | 18% | 0% | 21% | 12% | 18% | 3% | 3% | 6% | ||||
| Hodgkin lymphoma N = 33 | Mean score | 80 | 73 | 82 | 78 | 75 | 68 | 14 | 36 | 4 | 20 | 11 | 22 | 5 | 5 | 10 | 3.9 | 1.7 |
| % symptoms | 27% | 45% | 22% | 38% | 41% | 21% | 48% | 6% | 39% | 18% | 42% | 13% | 13% | 13% | ||||
| % severe symptoms | 12% | 21% | 9% | 13% | 16% | 9% | 24% | 0% | 15% | 9% | 18% | 3% | 3% | 9% | ||||
| Non-Hodgkin lymphoma N = 164 | Mean score | 78 | 73 | 83 | 84 | 82 | 68 | 23 | 33 | 5 | 16 | 11 | 22 | 8 | 9 | 11 | 4.1 | 1.3 |
| % symptoms | 34% | 44% | 24% | 28% | 30% | 38% | 55% | 8% | 33% | 21% | 46% | 20% | 21% | 19% | ||||
| % severe symptoms | 7% | 19% | 4% | 9% | 7% | 15% | 16% | 2% | 13% | 9% | 16% | 4% | 5% | 9% | ||||
| Multiple myeloma N = 54 | Mean score | 66 | 49 | 82 | 72 | 77 | 61 | 34 | 45 | 6 | 17 | 18 | 21 | 12 | 16 | 15 | 5.6 | 2.3 |
| % symptoms | 54% | 80% | 22% | 46% | 33% | 50% | 67% | 7% | 37% | 30% | 44% | 24% | 33% | 31% | ||||
| % severe symptoms | 15% | 44% | 7% | 19% | 15% | 24% | 26% | 4% | 9% | 20% | 13% | 9% | 11% | 9% | ||||
| Other N = 19 | Mean score | 77 | 66 | 70 | 76 | 80 | 61 | 22 | 40 | 3 | 22 | 22 | 28 | 14 | 9 | 11 | 4.9 | 2.2 |
| % symptoms | 28% | 50% | 47% | 42% | 47% | 42% | 56% | 0% | 33% | 33% | 56% | 16% | 16% | 21% | ||||
| % severe symptoms | 17% | 22% | 16% | 21% | 0% | 11% | 28% | 0% | 28% | 22% | 17% | 16% | 11% | 11% |
CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; AML, acute myeloid leukaemia.
% symptoms, proportion of patients scoring at most 67 for function scales or at least 33 for symptom scales.
% severe symptoms, proportion of patients scoring at most 34 for function scales or at least 66 for symptom scales.
No. of ‘symptoms’, mean number of symptoms using the same cut-point as in ‘% symptoms’ (quality of life excluded).
No. of ‘severe symptoms’, mean number of symptoms using the same cut-point as in ‘% severe symptoms’ (quality of life excluded).